Effect of &ohgr;-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA psychiatry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/jamapsychiatry.2016.2902PMID 27893018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Messages for Clinicians: Moderators and Mediators of Treatment Outcome in Randomized Clinical Trials.

  2016cited by this paper
• Four-Year Follow-up of Cognitive Behavioral Therapy in Persons at Ultra-High Risk for Developing Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.

  2016cited by this paper
• Why We Need a Transdiagnostic Staging Approach to Emerging Psychopathology, Early Diagnosis, and Treatment.

  2016cited by this paper
• Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra–high‐risk service

  2015cited by this paper
• Inflammation as a Predictive Biomarker for Response to Omega-3 Fatty Acids in Major Depressive Disorder: A Proof of Concept Study

  2015cited by this paper
• Disorder, not just state of risk: Meta-analysis of functioning and quality of life in people at high risk of psychosis

  2015cited by this paper
• Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study

  2015cited by this paper
• Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study

  2014cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2014cited by this paper
• Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients.

  2014cited by this paper
• Scale for the Assessment of Negative Symptoms

  2014cited by this paper
• The psychosis high-risk state: a comprehensive state-of-the-art review.

  2013cited by this paper
• The next stage for diagnosis: validity through utility

  2013cited by this paper
• Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups.

  2013cited by this paper
• Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?

  2013cited by this paper
• Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry.

  2013cited by this paper
• Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial

  2012cited by this paper
• Providing care to young people with emerging risk of psychosis: balancing potential risks and benefits

  2012cited by this paper
• Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study.

  2012cited by this paper
• Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial.

  2012cited by this paper
• Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk.

  2012cited by this paper
• Ultra high-risk state for psychosis and non-transition: a systematic review.

  2011cited by this paper
• A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis.

  2011cited by this paper
• Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study.

  2010cited by this paper
• Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry.

  2010cited by this paper
• Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

  2010cited by this paper
• Intervention in individuals at ultra-high risk for psychosis: a review and future directions.

  2009cited by this paper
• Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study.

  2009cited by this paper
• Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America.

  2008cited by this paper
• Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents.

  2007cited by this paper
• North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research.

  2007cited by this paper
• Clinical staging: a heuristic model for psychiatry and youth mental health

  2007cited by this paper
• Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?

  2007cited by this paper
• Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk.

  2007cited by this paper
• Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia.

  2007cited by this paper
• Clinical Staging of Psychiatric Disorders: A Heuristic Framework for Choosing Earlier, Safer and more Effective Interventions

  2006cited by this paper
• The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe.

  2005cited by this paper
• Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States

  2005cited by this paper
• Frühverlauf schizophrener Ersterkrankungen mit langer Dauer der unbehandelten Erkrankung - eine vergleichende Studie

  2004cited by this paper
• Early detection and secondary prevention of psychosis: facts and visions*

  2004cited by this paper
• Cognitive therapy for the prevention of psychosis in people at ultra-high risk

  2004cited by this paper
• Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features.

  2004cited by this paper
• Early Detection and Intervention in the Initial Prodromal Phase of Schizophrenia

  2003cited by this paper
• Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services

  2003cited by this paper
• Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group.

  2003cited by this paper
• Commentary: Progress, issues, and implications of prodromal research: an inside view.

  2003cited by this paper
• The assessment of "prodromal schizophrenia": unresolved issues and future directions.

  2003cited by this paper
• The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder.

  2003cited by this paper
• Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

  2002cited by this paper
• The Epidemiology of Schizophrenia: Prodrome, onset and early course of schizophrenia

  2002cited by this paper
• Duration of untreated psychosis: a critical examination of the concept and its importance

  2001cited by this paper
• Preventing severe mental illnesses--new prospects and ethical challenges.

  2001cited by this paper
• Ethics and early intervention in psychosis: keeping up the pace and staying in step.

  2001cited by this paper
• Diagnosing schizophrenia in the initial prodromal phase.

  2000cited by this paper
• Is Pre-Psychotic Intervention Realistic in Schizophrenia and Related Disorders?

  1997cited by this paper
• The Initial Prodrome in Psychosis: Descriptive and Qualitative Aspects

  1996cited by this paper
• EPPIC: an evolving system of early detection and optimal management.

  1996cited by this paper
• The prodromal phase of first-episode psychosis: past and current conceptualizations.

  1996cited by this paper
• Monitoring and care of young people at incipient risk of psychosis.

  1996cited by this paper
• Revising axis V for DSM-IV: a review of measures of social functioning.

  1992cited by this paper
• Duration of psychosis and outcome in first-episode schizophrenia.

  1992cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A Rating Scale for Mania: Reliability, Validity and Sensitivity

  1978cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper
• Risk of cancer in patients treated with human pituitary growth hormone in the UK , 1959 – 85 : a cohort study

  year unknowncited by this paper

• Feasibility of a Stepped‐Care Intervention for Those at Clinical High Risk for Psychosis in the United States

  2026influential citation
• Nutritional Management of Schizophrenia: Gut-Brain Axis Mechanisms and Dietary Interventions

  2026cites this paper
• Stepped care involving cognitive behavioral therapy for young people at clinical high-risk for psychosis in community settings: longitudinal intervention study protocol

  2025cites this paper
• Systematic Review and Meta-Analysis of Randomized Clinical Trials of Anti-Inflammatory Agents in Early-Stage Psychotic Disorders.

  2025cites this paper
• Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study

  2025influential citation
• Schizophrenia and psychosis in children and adolescents: An inspiring journey of scientific progress and the rich influences of history and religion.

  2025cites this paper
• Preventing psychosis in people at clinical high risk: an updated meta-analysis by the World Psychiatric Association Preventive Psychiatry section

  2025cites this paper
• Effect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis

  2025cites this paper
• Distribution of red blood cell fatty acids in stable patients with a schizophrenia spectrum disorder and healthy controls.

  2025cites this paper
• Learning health systems in early interventions for psychosis: Establishing consumer voices in clinical high-risk for psychosis care.

  2025cites this paper
• Cognitive impairments in first-episode psychosis patients with attenuated niacin response

  2025cites this paper
• Widespread but moderate genetic overlap between circulating polyunsaturated fatty acids and brain disorders

  2025cites this paper
• Annual Research Review: Psychosis in children and adolescents: key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk

  2025cites this paper
• Predictive role of erythrocyte fatty acids in conversion to psychosis: a longitudinal study of clinical high-risk individuals.

  2025cites this paper
• Positive and negative schizotypy personality traits are lower in individuals on ketogenic diet in a non-clinical sample.

  2024cites this paper
• Preventing disease progression in schizophrenia: What are we waiting for.

  2024cites this paper
• Review: Efficacy of preventative interventions for children and adolescents at clinical high risk of psychosis – a systematic review and meta‐analysis of intervention studies

  2024cites this paper
• Longitudinal trajectories of plasma polyunsaturated fatty acids and associations with psychosis-spectrum outcomes in early adulthood

  2024cites this paper
• Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk Individuals

  2024cites this paper
• Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra‐high risk in the UHR 1000+ cohort

  2024cites this paper
• Poly(4-methyl-1-pentene) hollow-fiber membranes with high plasma-leakage resistance prepared via thermally induced phase separation method

  2024cites this paper
• An open label pilot trial of low‐dose lithium for young people at ultra‐high risk for psychosis

  2024cites this paper
• Nutraceuticals in Psychiatric Disorders: A Systematic Review

  2024cites this paper
• Oméga-3 et psychiatrie : que dit la littérature ?

  2024cites this paper
• Advancements and Future Directions in Prevention Based on Evaluation for Individuals With Clinical High Risk of Psychosis: Insights From the SHARP Study.

  2024cites this paper
• Early Intervention in Psychosis: A Brief Narrative Review

  2024cites this paper
• The therapeutic effect of omega-3 polyunsaturated fatty acids on symptom severity of psychosis: A systematic review and meta-analysis

  2024cites this paper
• Omega-3 Fatty Acids and Neuroinflammation in Depression: Targeting Damage-Associated Molecular Patterns and Neural Biomarkers

  2024cites this paper
• Physical Health and Transition to Psychosis in People at Clinical High Risk

  2024cites this paper
• Omega-3 fatty acid supplementation for depression in children and adolescents.

  2024cites this paper
• Oxidative Stress in Schizophrenia: Relation to Neurochemical Pathogenetic Hypotheses

  2024cites this paper
• N-Acetylcysteine and a Specialized Preventive Intervention for Individuals at High Risk for Psychosis: A Randomized Double-Blind Multicenter Trial

  2024cites this paper
• Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial

  2024influential citation
• Omega-3 Supplementation Reduces Schizotypal Personality in Children: A Randomized Controlled Trial.

  2024cites this paper
• Nutrition in the Treatment of Schizophrenia: Rationale and Review of Recent Evidence

  2023cites this paper
• Recent Updates on Predicting Conversion in Youth at Clinical High Risk for Psychosis

  2023cites this paper
• Stress, Environment and Early Psychosis

  2023cites this paper
• Premorbid functioning in adolescence associates with comorbid disorders in individuals at ultra‐high risk for psychosis: A brief report

  2023cites this paper
• Nutrition and schizophrenia: associations worthy of continued revaluation

  2023cites this paper
• Complementary/Integrative Medicine Treatment and Prevention of Youth Psychosis.

  2023cites this paper
• Effect of Shi-Zhen-An-Shen herbal formula granule in the treatment of young people at ultra-high risk for psychosis: a pilot study

  2023cites this paper
• A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis

  2023cites this paper
• Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

  2023cites this paper
• Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT).

  2023cites this paper
• Cognitive-Behavioral Social Skills Training: Outcome of a Randomized Controlled Trial for Youth at Risk of Psychosis

  2023cites this paper
• Omega-3 supplements in the prevention and treatment of youth depression and anxiety symptoms: A scoping review

  2023cites this paper
• Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose–response meta-analysis of randomised controlled trials

  2023cites this paper
• A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study.

  2023cites this paper
• Can antipsychotics prevent transition to psychosis in high-risk population?

  2023cites this paper
• Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review

  2023cites this paper
• Immune and oxidative stress biomarkers in pediatric psychosis and psychosis-risk: Meta-analyses and systematic review

  2023cites this paper
• Shared genetic basis informs the roles of polyunsaturated fatty acids in brain disorders

  2023cites this paper
• Nutrition, Sleep, and Exercise as Healthy Behaviors in Schizotypy: A Scoping Review

  2022cites this paper
• Effects of Fish Oil Consumption On Psychological Function Outcomes in Psychosis: a Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.

  2022cites this paper
• Role of de novo lipogenesis in Insulin Resistance in First-episode Psychosis and Therapeutic Options.

  2022cites this paper
• Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

  2022cites this paper
• Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis

  2022cites this paper
• Baseline data of a sequential multiple assignment randomized trial (STEP study)

  2022cites this paper
• Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship

  2022cites this paper
• Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial

  2022cites this paper
• A Systematic Review of Omega-3 Consumption and Neuroprotective Cognitive Outcomes

  2022cites this paper
• Schizophrenia and Related Psychoses

  2021cites this paper
• Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials

  2021cites this paper
• Omega‐3 fatty acid in ultra‐high‐risk psychosis: A systematic review based on functional outcome

  2021cites this paper
• Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C.

  2021cites this paper
• The association between migrant status and transition in an ultra-high risk for psychosis population

  2021cites this paper
• Early Detection and Prevention of Schizophrenic Psychosis—A Review

  2021cites this paper
• [L'état mental à risque : au-delà de la prévention de la psychose].

  2021cites this paper
• Medikation

  2021cites this paper
• Skuteczność zapobiegania zaburzeniom psychicznym i ich leczenia: wnioski z badań dla praktyki klinicznej

  2021cites this paper
• Relationship between cognition and age at onset of first-episode psychosis: comparative study between adolescents, young adults, and adults

  2021cites this paper
• Intervention strategies for ultra-high risk for psychosis: Progress in delaying the onset and reducing the impact of first-episode psychosis.

  2021cites this paper
• The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: an analysis of the NEURAPRO clinical trial.

  2021cites this paper
• Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study.

  2021cites this paper
• Early Interventions for Clinical High-Risk State for Psychosis

  2021cites this paper
• Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids

  2021cites this paper
• Shared Decision Making With Young People at Ultra High Risk of Psychotic Disorder

  2021cites this paper
• Nutrition, Exercise, and Stress Management for Treatment and Prevention of Psychiatric Disorders. A Narrative Review Psychoneuroendocrineimmunology-Based

  2021cites this paper
• Computerized Assessment of Psychosis Risk

  2021cites this paper
• Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?

  2021cites this paper
• A Systematic Review of Effectiveness of Omega-3 Fatty Acid Supplementation on Symptoms, Social Functions, and Neurobiological Variables in Schizophrenia

  2021cites this paper
• Psychotic Disorders and Risk-States in Adolescence: Etiology, Developmental Considerations, and Treatment

  2021cites this paper
• Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders

  2021cites this paper
• Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis.

  2021cites this paper
• Plasma polyunsaturated fatty acids and mental disorders in adolescence and early adulthood: cross-sectional and longitudinal associations in a general population cohort

  2021cites this paper
• Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry

  2021cites this paper
• Causal associations between fatty acid measures and schizophrenia - a two-sample Mendelian randomization study

  2021cites this paper
• Cannabidiol for at risk for psychosis youth: A randomized controlled trial

  2021cites this paper
• Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.

  2021cites this paper
• Plasma metabolic alterations and potential biomarkers in individuals at clinical high risk for psychosis.

  2021cites this paper
• Greater preference for eveningness is associated with negative symptoms in an ultra‐high risk for psychosis sample

  2021cites this paper
• Bioactive lipids and brain function: from their mechanistic roles to clinical trials

  2021cites this paper
• Psychological interventions for people with psychotic experiences: A systematic review and meta-analysis of controlled and uncontrolled effectiveness and economic studies

  2020influential citation
• Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis.

  2020cites this paper
• Decreasing risk of psychosis by sulforaphane study protocol for a randomized, double‐blind, placebo‐controlled, clinical multi‐centre trial

  2020cites this paper
• Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data

  2020cites this paper
• Antipsychotic natural products

  2020cites this paper
• Has improved treatment contributed to the declining rate of transition to psychosis in ultra-high-risk cohorts?

  2020cites this paper
• Omega-3 Polyunsaturated Fatty Acids and Antioxidants for the Treatment of Schizophrenia: A Role for Magnetic Resonance Imaging

  2020cites this paper
• Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review

  2020cites this paper